A Multi-center, Open-label Clinical Trial to Evaluate the Objective Response Rate of Bevacizumab in Combination With Modified FOLFOX-6 Followed by One Year of Maintenance With Bevacizumab Alone in Patients With Initially Not or Borderline Resectable Colorectal Liver Metastases (The CLMO-001 Trial)

Trial Profile

A Multi-center, Open-label Clinical Trial to Evaluate the Objective Response Rate of Bevacizumab in Combination With Modified FOLFOX-6 Followed by One Year of Maintenance With Bevacizumab Alone in Patients With Initially Not or Borderline Resectable Colorectal Liver Metastases (The CLMO-001 Trial)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Levofolinic acid; Oxaliplatin
  • Indications Colon cancer; Liver metastases; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms ABOVE
  • Sponsors Roche
  • Most Recent Events

    • 22 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 07 Oct 2015 Planned End Date changed from 1 Jun 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
    • 19 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jan 2017 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top